

Growing consensus to support risk-driven breast care

> Standards of care may be about to shift as medical societies and associations align on support for early risk assessment.

Over 600,000 women die of breast cancer every year. Catching cancers earlier is the key to increasing the survival rate. Recent statistics indicate there has been a rise in aggressive, invasive breast cancer cases among young women – a population often excluded from breast screening which commonly begins at age 40.

Moving away from age-based screening to a risk-stratified approach is being recommended by a diverse group of organizations:



Age for Risk Assessment	Statement
25	"...undergo breast cancer risk assessment by age 25 and counselled regarding potential benefits, risks, and limitations of breast screening in the context of their risk stratification." ¹
No later than 30	"Higher-risk women should start mammographic screening earlier and may benefit from supplemental screening modalities. All women, especially black women and those of Ashkenazi Jewish decent, should be evaluated for breast cancer risk no later than age 30." ²
25	"Breast cancer risk assessment is very important for identifying women who may benefit from more intensive surveillance. There is no standardized approach which can result in applying average-risk screening recommendations to high-risk women." ³
25 and older	"...recommends that women age 25 and older undergo formal risk assessment for breast cancer including evaluation of indications for genetic testing and personal history of radiation, adding calculated lifetime risk using a validated model such as Tyrer-Cuzick at age 30 and beyond." ⁴

> **Personalized breast care pathways should start with risk assessment.**

PREDICT | MONITOR | DETECT | EMPOWER™

Risk assessments consider a multitude of risk factors to determine whether each patient needs genetic testing or should consider a different screening protocol than what's set for women at average risk – essentially getting higher-risk women the right test at the right time to inform care and prevention.

At Volpara, we support this personalized approach to breast screening as part of our mission to save families from cancer. Our comprehensive **Risk Pathways™** program makes evolving to risk assessment as standard of care easier and available to more women. Our integrated software seamlessly connects workflows inside and out of the mammography department, and excels coordinating care pathways for women identified at higher-risk of developing cancer. Volpara helps high-risk programs go beyond calculating the risk score to implementing appropriate interventions to prevent advanced stage cancers.

15 year

focus on breast cancer risk assessment

2 m⁺

breast cancer risk assessments performed annually

Integrated

with major electronic health records and genetic testing companies.

Contact

info@volparahealth.com
support@volparahealth.com

US +1 855 607 0478
AUS 1800 370 623
NZ 0800 444 148

Europe +44 203 051 1029
Global +64 4 499 6029

Connect

 @VolparaHealth

 @volpara

 Volpara Health

References

1. <https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419>
2. <https://www.sbi-online.org/RESOURCES/ScreeningMammography/TabId/111/ArtMid/1322/ArticleID/1039/New-ACRSBI-Guidelines-Recommend-All-Women-Be-Evaluated-For-Breast-Cancer-Risk-By-Age-30.aspx>
3. <https://www.acog.org/education-and-events/webinars/breast-and-ovarian-cancer-risk-assessment>
4. <https://www.breastsurgeons.org/docs/statements/Position-Statement-on-Screening-Mammography.pdf>